Lonza's Strategic Move: Acquisition of Biologics Site from Roche for $1.2 Billion
Wednesday, 20 March 2024, 10:14
Lonza's Recent Acquisition
Swiss contract drug manufacturer Lonza has recently entered into an agreement to buy a substantial biologics manufacturing site in California from Roche.
Key Industry Move
- This acquisition by Lonza represents a strategic shift towards strengthening its biologics manufacturing capabilities.
- Valued at $1.2 billion, this transaction underscores Lonza's commitment to expanding its presence in the biologics sector.
This strategic acquisition is expected to position Lonza as a key player in the global biologics market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.